Commentary: “Venous thromboembolism following surgery for pancreatic neuroendocrine neoplasms” Authors: Eileen Merriman Published: 2026 Venous thromboembolism (VTE) is the second most common cause of death in patients with malignancy. The highest incidence is within the first 6 months after a cancer diagnosis at 39.0 (95% CI, 38.2-39.9) per 1000 patient-years [1]. This is a serious issue, as VTE in cancer patients is associated with reduced survival, with Sørensen et al. [2] reporting a 1-year survival of 12% compared with 36% in a control group without VTE. Risk factors for cancer-associated VTE include tumor type (Figure), body mass index, and prechemotherapy hemoglobin, white blood cell, and platelet counts, all of which are incorporated into the Khorana score [3]. Pancreatic cancer is associated with the highest incidence rate, followed by liver, biliary, and non–small cell lung carcinoma [1].FigureVenous thromboembolism (VTE) incidence at 12 months by cancer type. Venous thromboembolism (VTE) incidence at 12 months by cancer type. Neuroendocrine tumors (NETs or NENs) are a rare group of malignancies arising from cells of the diffuse neuroendocrine system, with the most common site of involvement situated in the gastropancreatic tract [4]. There is a paucity of data on the incidence of thrombotic events in NETs. However, small case studies to date show that VTE rates in this group are likely very high, approaching those seen in pancreatic adenocarcinoma, which have been reported in 20% to 30% of patients during their disease course [5]. The increased thrombogenicity observed in NETs is thought to be due to high expression of proangiogenic factors, rich internal vascularity, vascular endothelial dysfunction, and possibly the release of tissue factor-positive microparticles [6]. Current guidelines for VTE prophylaxis following pancreatic adenocarcinoma surgery recommend the highest prophylactic dose of low-molecular-weight heparin, in the absence of contraindications, with prophylaxis extended to 4 weeks in all patients undergoing laparotomy or laparoscopic surgery with a low bleeding risk (grade 1A). However, guidelines for those with pancreatic NEN tumors (pNEN) are almost nonexistent, except for a recommendation from the European Neuroendocrine Tumor Society for perioperative VTE thromboprophylaxis confined to pNEN with glucagonomas [7]. Dong et al. [8] provide interesting, valuable data in their retrospective study, published in this issue of Research and Practice in Thrombosis and Haemostasis, which reports the incidence and risk factors for postoperative VTE in pNENs compared with other histologies. For this analysis, they accessed a large database containing 62,848 operations from more than 100 US hospital sites, reporting on 7609 patients with pNEN and 53,040 with non-pNEN pancreatic neoplasms. They report a 3.6% incidence of VTE among those undergoing surgery for pNEN, compared with 3.5% among those with non-pNEN histologies. In multivariate analysis, pNEN histology was not associated with an increased risk of VTE; however, pNEN patients had a higher adjusted risk of deep vein thrombosis (odds ratio, 1.25; 95% CI, 1.05-1.52). For those with pNEN, variables associated with an independently increased risk of VTE included longer operative times, higher body mass index, preoperative transfusion, total pancreatectomy, and long hospital stays. The main limitation of this study is that the incidence of VTE is somewhat lower than in previous studies of pancreatic and neuroendocrine malignancies, possibly due to the use of perioperative thromboprophylaxis, which was not well captured in this retrospective dataset. Additionally, rates were limited to VTE events within 30 days. Finally, the population eligible for surgery is a more selected subgroup with better functional status, fewer comorbidities, and earlier-stage disease. Nevertheless, the fact remains that there was no difference in VTE rates between pNEN and highly thrombogenic non-pNEN pancreatic neoplasms, with higher rates of deep vein thrombosis in pNEN patients. Prospective studies are needed to validate this finding, which, if confirmed, would necessitate that surgical thromboprophylaxis guidelines explicitly include the pancreatic pNEN group as high risk and require an equivalent thromboprophylaxis strategy. In this way, morbidity and mortality could be reduced in this rare but highly thrombogenic group.